SA
SCTX

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.1 · elevated volatility

Overview →

Scribe Therapeutics Inc. specializes in gene editing technologies, particularly its proprietary CRISPR platform, which aims to address genetic diseases. The company is positioned to capitalize on the growing demand for innovative therapies in the biotechnology sector, particularly in the U.S. and Europe.

HealthcareBiotechnologylow - The company operates with a high level of variable costs associated with R&D and clinical trials, limiting economies of scale.

Business Overview

01Collaborative partnerships with pharmaceutical companies - 100%

Scribe Therapeutics generates revenue primarily through strategic collaborations and licensing agreements with larger pharmaceutical firms, leveraging its advanced CRISPR technology to develop therapies for genetic disorders. The company's competitive advantage lies in its proprietary technology, which allows for more precise and efficient gene editing compared to traditional methods.

What Moves the Stock

Progress in clinical trials for lead gene therapy candidates

Partnership announcements with major pharmaceutical companies

Regulatory approvals from the FDA or EMA

Market adoption rates of gene editing therapies

Watch on Earnings
Progress in clinical trial phasesNumber of partnerships or collaborations establishedRegulatory milestones achieved

Risk Factors

Regulatory changes affecting gene editing technologies

Technological disruption from competing gene editing platforms

Emergence of new CRISPR technologies from competitors

Potential market saturation as more players enter the gene therapy space

Liquidity risks associated with funding ongoing clinical trials

Dependence on external funding sources for R&D

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The biotechnology sector can be sensitive to economic cycles, particularly in terms of funding for research and development, which may be influenced by GDP growth.

Interest Rates

Interest rates can affect Scribe's cost of capital for funding R&D projects. Higher rates may increase financing costs, impacting the company's ability to invest in new therapies.

Credit

minimal - The company does not have significant debt, reducing its exposure to credit market fluctuations.

Live Conditions
Dow Jones FuturesRussell 2000 FuturesS&P 500 Futures

Profile

growth - Investors are likely attracted to the potential for high returns from innovative therapies in a rapidly evolving market.

high - The stock may exhibit high volatility due to the binary nature of clinical trial outcomes and regulatory approvals.

Key Metrics to Watch
Clinical trial success rates
Number of active collaborations
FDA approval timelines
Market demand for gene therapies
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.